PRESS RELEASES

Date Title and Summary View
May 3, 2016
Summary ToggleZafgen to Host Conference Call to Discuss First Quarter 2016 Financial Results
BOSTON, May 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will host a conference call on Tuesday, May 10,
Summary ToggleZafgen to Host Conference Call to Discuss First Quarter 2016 Financial Results
Apr 3, 2016
Summary ToggleZafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016
--bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improvement in hyperphagia-related behaviors in PWS patients-- --Beloranib was associated with improvement in total cholesterol, LDL cholesterol and other markers of cardiometabolic risk -- --Beloranib
Summary ToggleZafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016
Mar 28, 2016
Summary ToggleZafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016
BOSTON, March 28, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that new scientific data from the bestPWS ZAF-311 study,
Summary ToggleZafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016
Mar 9, 2016
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2015 Financial Results

Conference Call Scheduled for 4:30 PM Eastern Time

Summary ToggleZafgen Reports Fourth Quarter and Full Year 2015 Financial Results
Mar 8, 2016
Summary ToggleZafgen Adds Thomas O. Daniel, M.D. to Its Board of Directors
BOSTON, March 08, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that Thomas O. Daniel, M.D.
Summary ToggleZafgen Adds Thomas O. Daniel, M.D. to Its Board of Directors
Mar 2, 2016
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results
BOSTON, March 02, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will host a conference call on Wednesday, March
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results
Mar 1, 2016
Summary ToggleZafgen to Present at the Cowen & Company 36th Annual Health Care Conference
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, Chief Executive Officer of Zafgen,
Summary ToggleZafgen to Present at the Cowen & Company 36th Annual Health Care Conference
Feb 29, 2016
Summary ToggleZafgen Joins NORD in Raising Awareness of Rare Disease Day Summary ToggleZafgen Joins NORD in Raising Awareness of Rare Disease Day
Feb 18, 2016
Summary ToggleZafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint
- Beloranib demonstrates statistically and clinically significant improvements in body weight and glycemic control over six months of randomized treatment — -Conference call scheduled for 8:30 AM Eastern Time- BOSTON, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical
Summary ToggleZafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint
Feb 16, 2016
Summary ToggleZafgen to Participate in Upcoming Investor Conferences
BOSTON, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will participate in two upcoming investor
Summary ToggleZafgen to Participate in Upcoming Investor Conferences